Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
eGuarantee, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 5%, Oct-Dec Ordinary Profit Increases by 3%
8771 eGuarantee,Inc. 【J-GAAP】
Earnings ReporteGuarantee,Inc. <8771> [TSE Prime] announced its financial results after the market closed on February 13th (15:30). The consolidated ordinary profit for the cumulative third quarter of the fiscal year ending March 2026 (April to December) increased 4.5% from the same period last year, reaching 3.98 billion yen. Progress toward the full-year plan of 5.30 billion yen was 75.2%, almost the same as the five-year average of 74.6%.
Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the January to March period (4Q) is expected to decrease 5.4% from the same period last year to 1.31 billion yen.
In the most recent three-month period, from October to December (3Q), the consolidated ordinary profit grew 3.1% from the same period last year, reaching 1.41 billion yen. However, the operating profit margin decreased from 52.0% in the same period last year to 49.2%.
Kabutan News
Actual Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Progress Rate vs. First Half | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Apr - Dec, 2023 | 6,821 | 3,631 | 3,652 | 2,408 | 50.7 | 74.5 | Jan 30, 2024 | J-GAAP |
| Apr - Dec, 2024 | 7,493 | 3,741 | 3,812 | 2,514 | 52.7 | 73.3 | Feb 10, 2025 | J-GAAP |
| Apr - Dec, 2025 | 8,253 | 3,872 | 3,984 | 2,685 | 57.6 | 75.2 | Feb 13, 2026 | J-GAAP |
| YoY | +10.1% | +3.5% | +4.5% | +6.8% | +9.3% |
Current Period Guidance
Second Half Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Mar, 2024 | 5,346 | 2,723 | 2,765 | 1,855 | 38.8 | 37 | May 14, 2025 | J-GAAP |
| Oct - Mar, 2025 Guidance | 5,812 | 2,688 | 2,732 | 1,810 | 40.9 | 38 | Nov 6, 2025 | J-GAAP |
| YoY | +8.7% | -1.3% | -1.2% | -2.4% | +5.2% |
Current Period Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Mar, 2024 | 9,165 | 4,850 | 4,902 | 3,262 | 68.6 | 35 | May 15, 2024 | J-GAAP |
| Mar, 2025 | 10,224 | 5,103 | 5,203 | 3,491 | 73.1 | 37 | May 14, 2025 | J-GAAP |
| Mar, 2026 Guidance | 11,300 | 5,200 | 5,300 | 3,550 | 80.1 | 38 | May 14, 2025 | J-GAAP |
| YoY | +10.5% | +1.9% | +1.9% | +1.7% | +9.6% |
Quarterly Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Dec, 2024 | 2,615 | 1,361 | 1,374 | 878 | 18.4 | 52.0 | Feb 10, 2025 | J-GAAP |
| Jan - Mar, 2025 | 2,731 | 1,362 | 1,391 | 977 | 20.5 | 49.9 | May 14, 2025 | J-GAAP |
| Apr - Jun, 2025 | 2,741 | 1,262 | 1,294 | 865 | 18.1 | 46.0 | Aug 7, 2025 | J-GAAP |
| Jul - Sep, 2025 | 2,747 | 1,250 | 1,274 | 875 | 18.5 | 45.5 | Nov 6, 2025 | J-GAAP |
| Oct - Dec, 2025 | 2,765 | 1,360 | 1,416 | 945 | 20.3 | 49.2 | Feb 13, 2026 | J-GAAP |
| YoY | +5.7% | -0.1% | +3.1% | +7.6% | +10.2% |
Related Articles
Foodison, Apr-Dec (Cumulative 3Q) Ordinary Profit Decreases by 8%
Terminalcare Support Institute, 49% Increase in Ordinary Profit for The Current Fiscal Year
Startia Holdings, Ordinary Profit Forecast for the Fiscal Year Revised Upward by 6%, Raises Record High Profit Forecast, Dividend Revised Upward by 10 Yen
SECURE, 2.0 times Increase in Ordinary Profit, Update Record High for Fourth Consecutive Term
Kubota Pharma, Last Fiscal Year's Net Income Loss Narrows, Current period performance is undisclosed.
Cuorips, Ordinary Profit Forecast for the Fiscal Year Loss Widened in Downward Revision
Nxera Pharma, Last Fiscal Year's Net Income Loss Widens, Current period performance is undisclosed.
MEEQ, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 63%, Oct-Dec Ordinary Profit Increases by 2.1 times
Thinca, The Current Fiscal Year's Net Income Turns to Loss
OPTORUN, 2.3 times Increase in Ordinary Profit for The Current Fiscal Year, Dividend Raised by 2 Yen